{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:16:32Z","timestamp":1788282992415,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018313","name":"Cleveland Eye Bank Foundation","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/100018313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Challenge Grant"],"award-info":[{"award-number":["Challenge Grant"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ajo.2026.06.038","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:17:01Z","timestamp":1782343021000},"page":"298-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions"],"prefix":"10.1016","volume":"290","author":[{"given":"Isabella H.","family":"Yazji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-5395","authenticated-orcid":false,"given":"Nadia J.","family":"Abbass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-9515","authenticated-orcid":false,"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-4181","authenticated-orcid":false,"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.06.038_sbref0001","series-title":"StatPearls","article-title":"Central retinal artery occlusion","author":"Tripathy","year":"2024"},{"key":"10.1016\/j.ajo.2026.06.038_sbref0002","series-title":"StatPearls","article-title":"Central retinal vein occlusion","author":"Blair","year":"2024"},{"issue":"5","key":"10.1016\/j.ajo.2026.06.038_bib0003","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41433-018-0066-7","article-title":"Statins in retinal disease","volume":"32","author":"Al-Janabi","year":"2018","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.ajo.2026.06.038_bib0004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","article-title":"Cardiovascular Risk Factors for Retinal Vein Occlusion and Arteriolar Emboli: the Atherosclerosis Risk in Communities & cardiovascular Health studies","volume":"112","author":"Wong","year":"2005","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2026.06.038_bib0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archopht.1996.01100130537006","article-title":"Risk factors for central retinal vein occlusion","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.038_bib0006","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.66.3.161","article-title":"Retinal vein occlusion and the prevalence of lipoprotein abnormalities","volume":"66","author":"Dodson","year":"1982","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.06.038_bib0007","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00417-016-3569-6","article-title":"Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion","volume":"255","author":"Matei","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2026.06.038_bib0008","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2023035","article-title":"Impact of statin treatment on cardiovascular events in patients with retinal vein occlusion: a nested case-control study in Korea","volume":"45","author":"Yoo","year":"2023","journal-title":"Epidemiol Health"},{"issue":"6","key":"10.1016\/j.ajo.2026.06.038_bib0009","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00417-017-3606-0","article-title":"Effect of oral niacin on central retinal vein occlusion","volume":"255","author":"Gaynon","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.06.038_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107633","article-title":"Efficacy and safety of PCSK9 inhibitors for stroke prevention: systematic review and meta-analysis","volume":"33","author":"Moustafa","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.038_bib0011","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranh\u00e3o","year":"2014","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.038_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7_supplement_1","key":"10.1016\/j.ajo.2026.06.038_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000205773","article-title":"The effect of PCSK-9 inhibitors on incidence of stroke: A systematic review and meta-analysis (P3-5.001)","volume":"102","author":"Elsayed","year":"2024","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ajo.2026.06.038_bib0014","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.numecd.2021.03.026","article-title":"The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis","volume":"31","author":"Qin","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.ajo.2026.06.038_bib0015","unstructured":"Unified Medical Language System (UMLS). National Library of Medicine. Accessed July 23, 2025. https:\/\/www.nlm.nih.gov\/research\/umls\/index.html."},{"key":"10.1016\/j.ajo.2026.06.038_bib0016","unstructured":"STROBE. Strengthening the reporting of observational studies in epidemiology. Accessed July 25, 2025. https:\/\/www.strobe-statement.org\/."},{"issue":"10","key":"10.1016\/j.ajo.2026.06.038_bib0017","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1167\/iovs.08-1826","article-title":"Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis","volume":"49","author":"Cheung","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.06.038_bib0018","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/archopht.126.5.692","article-title":"Retinal vein occlusion and traditional risk factors for atherosclerosis","volume":"126","author":"O\u2019Mahoney","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.038_bib0019","article-title":"Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data","volume":"2014","author":"Kolar","year":"2014","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.038_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91401-1","article-title":"Clinical significance of subclinical atherosclerosis in retinal vein occlusion","volume":"11","author":"Lyu","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ajo.2026.06.038_bib0021","first-page":"338","article-title":"Lipoprotein (a): a risk factor for retinal vascular occlusion","volume":"1","author":"M\u00fcller","year":"1992","journal-title":"Ger J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.06.038_bib0022","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2009.11.006","article-title":"High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion","volume":"210","author":"Sofi","year":"2010","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ajo.2026.06.038_bib0023","first-page":"245","article-title":"[Retinal vein occlusion and lipoprotein (a)]","volume":"21","author":"Ribeaudeau-Saindelle","year":"1998","journal-title":"J Fr Ophtalmol"},{"issue":"18","key":"10.1016\/j.ajo.2026.06.038_bib0024","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.3390\/ijerph18189864","article-title":"Association between Statins and Retinal Vascular Occlusion: A Population-Based Cohort Study","volume":"18","author":"Chien","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"9841","key":"10.1016\/j.ajo.2026.06.038_bib0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ajo.2026.06.038_bib0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ajo.2026.06.038_bib0027","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2026.06.038_bib0028","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.amjcard.2019.09.011","article-title":"Meta-analysis of randomized controlled trials assessing the impact of proprotein convertase subtilisin\/Kexin Type 9 antibodies on mortality and cardiovascular outcomes","volume":"124","author":"AlTurki","year":"2019","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.ajo.2026.06.038_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295359","article-title":"Proprotein convertase subtilisn\/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"18","author":"Imran","year":"2023","journal-title":"PLOS One"},{"key":"10.1016\/j.ajo.2026.06.038_bib0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/heartjnl-2019-314763","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis","volume":"105","author":"Du","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.ajo.2026.06.038_bib0031","first-page":"982","article-title":"Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors\u2014an observational study","volume":"19","author":"N\u00e4gele","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajo.2026.06.038_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2023.104513","article-title":"Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function","volume":"148","author":"Schremmer","year":"2023","journal-title":"Microvasc Res"},{"issue":"3","key":"10.1016\/j.ajo.2026.06.038_bib0033","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","article-title":"Improved endothelial function after short-term therapy with evolocumab","volume":"12","author":"Maulucci","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajo.2026.06.038_bib0034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","article-title":"Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy","volume":"194","author":"Minno","year":"2020","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.ajo.2026.06.038_bib0035","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00592-021-01703-z","article-title":"Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL\u2014cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting","volume":"58","author":"Scicali","year":"2021","journal-title":"Acta Diabetol"},{"issue":"10","key":"10.1016\/j.ajo.2026.06.038_bib0036","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of proprotein convertase subtilisin\/Kexin Type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426003478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:32:17Z","timestamp":1788280337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426003478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0002939426003478"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.038","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}